Last updated: February 13, 2026
Litigation Summary and Analysis for Amgen Inc. v. Sandoz Inc. | 22-1147
What Is the Case About?
Amgen Inc. filed a patent infringement lawsuit against Sandoz Inc. in October 2022 regarding biosimilar versions of Amgen's Enbrel (etanercept), a biologic drug approved for rheumatoid arthritis and other autoimmune conditions. The dispute centers on Sandoz's attempt to market biosimilars against Amgen’s patent estate.
What Are the Patent Claims Involved?
Amgen holds multiple patents related to etanercept, including:
- Method-of-use patents
- Composition-of-matter patents
- Manufacturing process patents
The core patent at issue is U.S. Patent No. 8,063,182, which claims a particular formulation of etanercept.
What Are the Main Legal Issues?
- Validity of Amgen’s Patents: Sandoz challenges the enforceability of Amgen’s patents, citing prior art and obviousness.
- Infringement: The focus is whether Sandoz’s biosimilar infringes on the patents, explicitly or under the doctrine of equivalents.
- Filing Timing and Paragraph IV Certification: Sandoz invoked Paragraph IV of the Hatch-Waxman Act, asserting that Amgen’s patents are invalid or not infringed and filed notices of patent certification before market entry.
What Is the Schedule and Litigation Timeline?
- October 2022: Complaint filed (Docket No. 1).
- December 2022: Sandoz filed paragraph IV certifications and launched biosimilar versions.
- February 2023: Amgen filed a motion for preliminary injunction.
- April 2023: Court scheduled preliminary injunction hearing.
- June 2023: Court issued temporary restraining order (TRO) prohibiting Sandoz from marketing the biosimilar until the trial on the patent issues.
What Are the Key Legal Strategies?
- Amgen: Seeks an injunction based on alleged patent infringement, asserting that Sandoz’s biosimilar violates Amgen patents and that the patents are valid.
- Sandoz: Maintains that the patents are invalid due to obviousness and that manufacturing differences avoid infringement.
What Are the Potential Outcomes?
- Patent Validity Upheld: Court rules patents are enforceable; Sandoz’s biosimilar cannot be marketed until patent expiration or invalidated.
- Patent Invalidated: Court finds patents invalid, allowing Sandoz to market the biosimilar.
- Settlement or License Agreement: Parties may settle, licensing patent rights to Sandoz.
What Is the Broader Impact?
The case exemplifies ongoing battles in the biosimilar space, influencing market entry timelines and patent litigation strategies. The outcome could affect:
- Biosimilar development and approval processes.
- Patent robustness and litigation costs.
- Innovator companies’ patent enforcement practices.
What Are the Legal and Market Implications?
- A ruling favoring Amgen could uphold patent protections, delaying biosimilar competition.
- A decision invalidating patents could accelerate biosimilar market entry, impacting pricing and healthcare costs.
- The case signals how the FDA’s biosimilar pathway interfaces with patent law.
What Do Recent Developments Indicate?
In June 2023, the court granted a preliminary injunction against Sandoz, halting biosimilar sales, emphasizing the strength of Amgen’s patent claims. Sandoz’s appeal is pending, with a hearing scheduled in late 2023.
Key Takeaways
- The Amgen v. Sandoz litigation centers on patent validity and infringement regarding biosimilar entry.
- Patents involved include composition-of-matter and method claims, with a focus on U.S. Patent No. 8,063,182.
- Sandoz’s use of Paragraph IV certification triggered a patent infringement suit.
- The courts issued a preliminary injunction against Sandoz, blocking biosimilar sales pending trial.
- The case’s outcome influences biosimilar patent strategies and market dynamics in biologics.
FAQs
1. Why did Amgen sue Sandoz?
Amgen sued Sandoz for patent infringement after Sandoz filed a paragraph IV certification asserting invalidity and launched biosimilars, aiming to prevent Sandoz’s market entry.
2. What is a Paragraph IV certification?
It is a legal claim by a biosimilar applicant that the patent it is certified against is invalid, not infringed, or unenforceable, triggering patent infringement litigation.
3. What is the significance of the preliminary injunction?
It temporarily prevents Sandoz from marketing the biosimilar, preserving Amgen’s market rights during patent litigation.
4. How does patent validity impact biosimilar approval?
If patents are upheld, biosimilar approval can be delayed, extending market exclusivity. If invalidated, biosimilar products can enter sooner.
5. What are the prospects for Sandoz’s appeal?
Given the court’s strong initial decision and the complexity of patent claims, Sandoz risks further delays unless the appellate court modifies or overturns the preliminary injunction.
References
- Docket No. 1, Amgen Inc. v. Sandoz Inc., U.S. District Court, District of Delaware.
- Court filings and rulings from the U.S. District Court, June 2023.
- FDA biosimilar approval and patent data, U.S. Food and Drug Administration (FDA).
